Photo from wikipedia
Key Points Question Does the addition of apatinib, a vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, to treatment with pegylated liposomal doxorubicin (PLD) improve progression-free survival in patients… Click to show full abstract
Key Points Question Does the addition of apatinib, a vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, to treatment with pegylated liposomal doxorubicin (PLD) improve progression-free survival in patients with platinum-resistant recurrent ovarian cancer? Findings In the APPROVE randomized clinical trial that included 152 patients with platinum-resistant recurrent ovarian cancer, the median progression-free survival in the apatinib plus PLD group was 5.8 months compared with 3.3 months in the PLD alone group. Meaning The trial results found that apatinib plus PLD may be a novel alternative treatment option for patients with platinum-resistant recurrent ovarian cancer.
Journal Title: JAMA Oncology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!